Pyxis Oncology Inc (PYXS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.89+8.96%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PYXS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 349.3% |
| Our one-year growth estimate | diamond | 7.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 341.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PYXS — earnings miss
Dated 2026-08-13
of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.
Why it matters: Progress on this product is key for future growth. Positive updates could boost investor confidence.
Supportive ifManagement gives a good update on clinical trials or progress for MICVO.
Worry ifThere are no updates or bad news about MICVO development.
Why it matters: A big rise in net loss could worry investors. They will watch the company's financial health closely.
Worry ifNet loss reported is worse than $23.3 million from Q1 2026.
Less concerning ifNet loss reported is equal to or better than $23.3 million from Q1 2026.
Why it matters: The loss of a key director may change company plans and actions.
Worry ifManagement has a clear plan after the departure. This helps investors feel more confident.
Less concerning ifMore leadership changes or no clear direction after the departure.
Why it matters: The company has more cash, which is important for funding clinical trials.
Supportive ifManagement says cash will last into the second quarter of 2027, helping ongoing trials.
Worry ifManagement says cash will run out sooner than expected, raising funding concerns.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$479 on $10,000 · ±4.8% | How much price usually moves either way. |
| Bad day | $845 loss on $10,000 · 8.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,736 loss on $10,000 · 27.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This data will reveal how MICVO works with pembrolizumab for first-line head and neck cancer patients. It's crucial for future development.
Supportive ifNew data shows good results for MICVO with pembrolizumab for 1L R/M HNSCC.
Worry ifData shows poor results. This suggests problems with the combination therapy.
Why it matters: Confirming the cash runway is important for funding clinical trials. It shows the company can run its operations without needing money right away.
Supportive ifThe company confirms it has enough cash to fund operations into Q2 2027.
Worry ifThe company says it needs more money before Q2 2027.
Why it matters: This data will show how well MICVO works for patients with head and neck cancer. Positive results could boost confidence in the drug's potential.
Supportive ifNew data shows better safety and effectiveness for patients at or below the dose cap.
Worry ifData shows no improvement or worse results in treated patients.